|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 23, 2016 ) Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.
The demand for albumin is high in APAC in countries like India and China. Still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. Thus, the awareness programs conducted by organizations such as PPTA, which includes International Plasma Awareness Week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions.
Publisher's analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020.
For more information about this report: http://www.reportsweb.com/global-human-albumin-market-2016-2020
Covered in this report
The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Publisher's report, Global Human Albumin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- CSL Behring
- Grifols
- Baxalta
- Octapharma
- Kedrion
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001303215/sample
Other prominent vendors
- AADi
- Ablynx
- Albumedix
- Ampio Pharmaceuticals
- Azaya Therapeutics
- Beijing Tiantan
- Biotest
- Bristol-Myers Squibb
- Celgene
- ConjuChem
- GSK
- Hebei Changshan Biochem Pharma
- HiMedia Laboratories
- Hualan Biological Engineering
- InVittria
- MedxBio
- Merck
- Mitsubishi Tanabe Pharma
- NantBioScience
- Novo Nordisk
- Novozymes
- Shanghai RAAS Blood Products
- Sucampo Pharmaceuticals
- Teva Pharmaceuticals
- Thermo Fisher Scientific
- Tianjin SinoBiotech & Beijing Bio-Fortune
- Ventria Bioscience
- Yoshitomi Pharmaceutical
Market driver
- High demand for human albumin in China
- For a full, detailed list, view our report
Market challenge
- Spread of pathogenic contaminants
- For a full, detailed list, view our report
Market trend
- Rise in non-therapeutic applications
- For a full, detailed list, view our report
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001303215/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
